Updated to include the offering’s pricing information.
Ocular Therapeutix (NSDQ:OCUL) said today that it plans to launch an underwritten public offering of 6.5 million shares of common stock at $5.00 apiece to help fund the resubmission of its new drug application for Dextenza, an ocular post-surgical pain-relief implant that was rejected by the FDA last year.
The Bedford, Mass.-based company said it will also offer underwriters a 30-day option to buy an additional 15% of the shares in the offering on the same terms.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocular Therapeutix plans $32.5m public offering to fund NDA resubmission for Dextenza appeared first on MassDevice.